company background image
ALTH

Theraclion ENXTPA:ALTHE Stock Report

Last Price

€1.20

Market Cap

€34.4m

7D

-4.8%

1Y

-29.2%

Updated

23 May, 2022

Data

Company Financials +
ALTHE fundamental analysis
Snowflake Score
Valuation0/6
Future Growth2/6
Past Performance0/6
Financial Health0/6
Dividends0/6

ALTHE Stock Overview

Theraclion SA develops echotherapy solutions using high intensity focused ultrasound system.

Theraclion Competitors

 

 

 

 

 

 

 

 

 

 

 

 

Price History & Performance

Summary of all time highs, changes and price drops for Theraclion
Historical stock prices
Current Share Price€1.20
52 Week High€2.28
52 Week Low€0.91
Beta0.78
1 Month Change-5.14%
3 Month Change-14.29%
1 Year Change-29.20%
3 Year Change-9.43%
5 Year Change-78.18%
Change since IPO-90.88%

Recent News & Updates

Shareholder Returns

ALTHEFR Medical EquipmentFR Market
7D-4.8%1.1%-1.5%
1Y-29.2%-6.3%-18.8%

Return vs Industry: ALTHE underperformed the French Medical Equipment industry which returned -5.9% over the past year.

Return vs Market: ALTHE underperformed the French Market which returned -5.4% over the past year.

Price Volatility

Is ALTHE's price volatile compared to industry and market?
ALTHE volatility
ALTHE Average Weekly Movement7.0%
Medical Equipment Industry Average Movement7.1%
Market Average Movement6.0%
10% most volatile stocks in FR Market10.2%
10% least volatile stocks in FR Market3.5%

Stable Share Price: ALTHE is not significantly more volatile than the rest of French stocks over the past 3 months, typically moving +/- 7% a week.

Volatility Over Time: ALTHE's weekly volatility (7%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
2004n/aDavid Caumartinhttps://www.theraclion.com

Theraclion SA develops echotherapy solutions using high intensity focused ultrasound system. It offers SONOVEIN, a robotic solution for non-invasive echotherapy treatment of varicose veins; ECHOPULSE, a robotic and non-invasive solution for echotherapy treatment of thyroid nodules and breast fibroadenoma; and EPack, a disposable that is installed on the device before treatment and protects the patient’s skin and optimizes the image quality. The company was founded in 2004 and is based in Malakoff, France.

Theraclion Fundamentals Summary

How do Theraclion's earnings and revenue compare to its market cap?
ALTHE fundamental statistics
Market Cap€34.45m
Earnings (TTM)-€3.76m
Revenue (TTM)€1.68m

20.5x

P/S Ratio

-9.2x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
ALTHE income statement (TTM)
Revenue€1.68m
Cost of Revenue€2.88m
Gross Profit-€1.19m
Other Expenses€2.57m
Earnings-€3.76m

Last Reported Earnings

Dec 31, 2021

Next Earnings Date

n/a

Earnings per share (EPS)-0.13
Gross Margin-70.78%
Net Profit Margin-223.28%
Debt/Equity Ratio0.0%

How did ALTHE perform over the long term?

See historical performance and comparison

Valuation

Is Theraclion undervalued compared to its fair value and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

  • Below Fair Value

  • Significantly Below Fair Value

  • PE vs Industry

  • PE vs Market

  • PEG Ratio

  • PB vs Industry

In this section, we usually try to help investors determine whether Theraclion is trading at an attractive price based on the cash flow it is expected to produce in the future. But as Theraclion has not provided consistent financial data, and the stock also has no analyst forecast or coverage, its intrinsic value cannot be reliably calculated by extrapolating past data or using analyst consensus cash flow predictions.

This is quite a rare situation as 89% of companies covered by Simply Wall St do have a valuation analysis.


Future Growth

How is Theraclion forecast to perform in the next 1 to 3 years based on estimates from 1 analyst?

Future Growth Score

2/6

Future Growth Score 2/6

  • Earnings vs Savings Rate

  • Earnings vs Market

  • High Growth Earnings

  • Revenue vs Market

  • High Growth Revenue

  • Future ROE


81.2%

Forecasted annual revenue growth

Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: Insufficient data to determine if ALTHE's forecast earnings growth is above the savings rate (0.3%).

Earnings vs Market: Insufficient data to determine if ALTHE's earnings are forecast to grow faster than the French market

High Growth Earnings: Insufficient data to determine if earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: ALTHE's revenue (81.2% per year) is forecast to grow faster than the French market (5.8% per year).

High Growth Revenue: ALTHE's revenue (81.2% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if ALTHE's Return on Equity is forecast to be high in 3 years time


Past Performance

How has Theraclion performed over the past 5 years?

Past Performance Score

0/6

Past Performance Score 0/6

  • Quality Earnings

  • Growing Profit Margin

  • Earnings Trend

  • Accelerating Growth

  • Earnings vs Industry

  • High ROE


14.7%

Historical annual earnings growth

Earnings and Revenue History

Quality Earnings: ALTHE is currently unprofitable.

Growing Profit Margin: ALTHE is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: ALTHE is unprofitable, but has reduced losses over the past 5 years at a rate of 14.7% per year.

Accelerating Growth: Unable to compare ALTHE's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: ALTHE is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (22.5%).


Return on Equity

High ROE: ALTHE has a negative Return on Equity (0%), as it is currently unprofitable.


Financial Health

How is Theraclion's financial position?

Financial Health Score

0/6

Financial Health Score 0/6

  • Short Term Liabilities

  • Long Term Liabilities

  • Debt Level

  • Reducing Debt

  • Stable Cash Runway

  • Forecast Cash Runway

Financial Position Analysis

Short Term Liabilities: Insufficient data to determine if ALTHE's short term assets cover its short term liabilities.

Long Term Liabilities: Insufficient data to determine if ALTHE's short term assets cover its long term liabilities.


Debt to Equity History and Analysis

Debt Level: Insufficient data to calculate ALTHE's net debt to equity ratio to determine if it is satisfactory.

Reducing Debt: Insufficient data to determine if ALTHE's debt to equity ratio has reduced over the past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: Insufficient data to determine if ALTHE has enough cash runway based on its current free cash flow.

Forecast Cash Runway: Insufficient data to determine if ALTHE has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.


Dividend

What is Theraclion current dividend yield, its reliability and sustainability?

Dividend Score

0/6

Dividend Score 0/6

  • Notable Dividend

  • High Dividend

  • Stable Dividend

  • Growing Dividend

  • Earnings Coverage

  • Future Dividend Coverage

Dividend Yield vs Market

Notable Dividend: Unable to evaluate ALTHE's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate ALTHE's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if ALTHE's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if ALTHE's dividend payments have been increasing.


Earnings Payout to Shareholders

Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as ALTHE has not reported any payouts.


Discover strong dividend paying companies

Management

How experienced are the management team and are they aligned to shareholders interests?

7.7yrs

Average management tenure


CEO

David Caumartin

7.67yrs

Tenure

€293,758

Compensation

Mr. David Caumartin has been the Chief Executive Officer of Theraclion SA since September 30, 2014. Mr. Caumartin is healthcare industry specialist with experience at GE Healthcare, covering Europe, Middle...


CEO Compensation Analysis

Compensation vs Market: Insufficient data to establish whether David's total compensation is reasonable compared to companies of similar size in the French market.

Compensation vs Earnings: David's compensation has been consistent with company performance over the past year.


Leadership Team

Experienced Management: ALTHE's management team is seasoned and experienced (7.7 years average tenure).


Board Members

Experienced Board: ALTHE's board of directors are considered experienced (3.1 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have been substantially diluted in the past year, with total shares outstanding growing by 72.7%.


Top Shareholders

Company Information

Theraclion SA's employee growth, exchange listings and data sources


Key Information

  • Name: Theraclion SA
  • Ticker: ALTHE
  • Exchange: ENXTPA
  • Founded: 2004
  • Industry: Health Care Equipment
  • Sector: Healthcare
  • Implied Market Cap: €34.449m
  • Shares outstanding: 28.71m
  • Website: https://www.theraclion.com

Number of Employees


Location

  • Theraclion SA
  • 102 Rue Etienne Dolet
  • Malakoff
  • Ile-de-France
  • 92240
  • France

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2022/05/23 00:00
End of Day Share Price2022/05/23 00:00
Earnings2021/12/31
Annual Earnings2021/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.